Skip to main content

Table 1 Summary of included studies

From: Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis

Studies

Year published

Study period (months)

Medication

Disease

N in drug group

N in placebo group

Metric of FVC change used in meta-analysis

All-cause mortality available

Richeldi et al. TOMORROW trial

2011

12

Nintedanib

IPF

84

83

mls/year

Yes

Richeldi et al. INPULSIS trial 1

2014

12

Nintedanib

IPF

309

204

mls/year

Yes

Richeldi et al. INPULSIS trial 2

2014

12

Nintedanib

IPF

329

219

mls/year

Yes

Flaherty et al. INBUILD trial

2019

12

Nintedanib

Non-IPF

206

206

mls/year

Yes

Distler et al. NCT 02597933

2019

12

Nintedanib

Non-IPF

288

288

mls/year

Yes

Azuma et al.

2005

9

Pirfenidone

IPF

73

36

mls over 9 months

No

Taniguchi et al.

2010

12

Pirfenidone

IPF

108

104

mls/year

No

Noble et al. CAPACITY NCT 00287729

2011

18

Pirfenidone

IPF

174

174

% predicted FVC

Yes

Noble et al. CAPACITY NCT 00287716

2011

18

Pirfenidone

IPF

171

173

% predicted FVC

Yes

Huang et al.

2015

11

Pirfenidone

IPF

38

38

mls over study period

Yes

King et al. ASCEND trial

2014

12

Pirfenidone

IPF

278

277

Slope of fall in FVC mls

Yes

Maher et al.

2020

6

Pirfenidone

Non-IPF

118

119

mls FVC over study period

Yes

Behr et al.s

2021

11

Pirfenidone

Non-IPF

35

32

% predicted FVC

Yes